Tiziana Life Sciences Ltd TLSA
Annual
Quarterly
No annual revenue total was found in Tiziana Life Sciences Ltd's SEC filings.
Tiziana Life Sciences Ltd (TLSA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$1.5 million. As of Dec 31, 2024 it held $3.7 million in cash and investments and $106,000 in total debt.
Revenue
—
Net income
$-11.86M
+32.9% vs prior year
Operating cash flow
$-1.53M
+90.3% vs prior year
Free cash flow
$-1.54M
+92.9% vs prior year
EPS
$-0.11
+35.3% vs prior year
Dividend per share
None
Shares outstanding
120.51M
+8.1% vs prior year
Net cash
$3.62M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TLSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Bermuda
- Headquarters
- London, England, United Kingdom
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1723069
- Former names
- Tiziana Life Sciences plc (until Oct 21, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Operating income | -$15.8M | -$18.0M | -$14.6M | -$27.4M | -$28.0M |
| Net income | -$11.9M | -$17.7M | -$15.4M | -$23.4M | -$26.1M |
| Diluted EPS | -$0.11 | -$0.17 | -$0.15 | — | — |
| Operating cash flow | -$1.5M | -$15.7M | -$19.6M | -$21.8M | -$11.3M |
| Free cash flow | -$1.5M | — | — | -$21.8M | -$11.3M |
| Total assets | $11.3M | $12.2M | $26.5M | $48.8M | $70.7M |
| Total liabilities | $7.3M | $6.6M | $6.9M | $7.5M | $8.3M |
| Stockholders' equity | $3.9M | $5.5M | $19.6M | $41.3M | $62.4M |
| Cash and investments | $3.7M | $1.2M | $18.1M | $42.2M | $65.8M |
| Total debt | $106,000 | $138,000 | $130,000 | — | $879,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K/A | Amendment no. 1 to form 6-k | Nov 2, 2026 | Oct 16, 2026 |
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 16, 2026 | Oct 16, 2026 |
| 6-K | Current report (foreign issuer) | Oct 16, 2026 | Oct 16, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
All 491 Tiziana Life Sciences Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.